Blood Plasma Derivatives Market Statistics 2030
The global blood plasma derivatives market size was valued at $36,471.9 million in 2020, and is projected to reach $89,767 million by 2030, registering a CAGR of 9.4% from 2021 to 2030. Plasma is a straw colored clear liquid component of the blood which is a protein salt solution. There are three types of blood cells such as the red blood cells, white blood cells, and platelets, which are suspended in the plasma. Plasma contains more than 100 different proteins such as albumin, fibrinogen, immunoglobulin, protease inhibitors, & clotting factor. It plays important role in maintaining the blood pressure & exchanging the minerals such as sodium & potassium.
Immunoglobulin constitutes the major & important role in maintenance of the osmotic pressure in blood vessels. Immunoglobulin are responsible for development of the immunity when any foreign particle enters into the body.The rise in prevalence of life-threatening disorders such as immunodeficiency, the rise in geriatric population, and growth in adoption of blood plasma derivatives products are expected to drive the market. The global blood plasma market report provides a holistic evaluation of the market during the forecast period. The report comprises various segments as well as an analysis of the trends and factors that play a substantial role in the market.
The blood plasma product possesses various advantages including the coagulation of blood, defense, nutrition, regulation of acid –base balance, maintenance of the osmotic pressure, respiration, excretion, & controlling body temperature. This factor is responsible for growth of the blood plasma market.
Impact Of Covid-19 On Blood Plasma Derivatives Market (Pre And Post Analysis)
Furthermore, increase in number of approval for blood plasma products drives growth of the market. In addition, surge in number of clinical studies for evaluating safety and efficiency of a wide range of therapeutic drugs is anticipated to contribute toward growth of the blood plasma derivatives market. According to the journal of BMC Infectious Disease, in November 2021, it was reported that the convalescent plasma therapy treatment is used for the patient infected with the COVID-19 .The Meta -analysis clinical trial is conducted to analyze the efficiency and effectiveness of convalescent plasma. The result shows decrease in the mortality rate in COVID-19 patient by convalescent plasma treatment.
Furthermore, rise in R&D activities to develop advanced plasma derived product is expected to provide remunerative opportunities for expansion of the global blood plasma derivatives products market during the forecast period. Moreover, presence of key manufacturing companies to manufacture and distribute plasma products and rise in expenditure on healthcare products propel growth of the market.
Initiatives taken by government and private organizations to develop pharmaceutical industry propel the growth of the market. However, the side effects caused due to use of blood plasma derivative such as allergic condition, dizziness, fast heartbeats, shortness in breath are expected to restrict the blood plasma derivatives market growth during the forecast period.
Global Blood Plasma Derivatives Market Segmentation
The blood plasma derivatives market is segmented into type, application, and end user. By type, the market is categorized albumin, factor VIII, factor IX, immunoglobulin hyperimmune globulin, & others. On the basis of application, it is divided into hemophilia, hypogamma globulinemia, immunodeficiency diseases, von willebrand's disease, and other application. Depending on end user, it is categorized into hospitals, clinics, and other end user. Region wise, the blood plasma derivatives market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China, India, and rest of Asia-Pacific), and LAMEA (Saudi Arabia, the UAE, Russia, Kazakhstan, Azerbaijan, Iran, Algeria, Egypt, and rest of LAMEA).
By Type
Depending on type, the immunoglobulin segment dominated the blood plasma derivatives market in 2020, and this trend is expected to continue during the forecast period, owing to advancements in R&D activities in the healthcare sector and increase in prevalence of immune deficient disorder. However, the albumin segment is expected to witness considerable growth during the forecast period due to increase in albumin product usage for non-therapeutic application, and rise in adoption of albumin products.
By Type
Immunoglobulin segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.
By Application
By application, the other application segment was the major contributor in 2020, and is expected to maintain its lead during the forecast period, owing to increase in prevalence of infectious disease, and increase in demand for plasma derived product. However, the immunodeficiency diseases segment is expected to witness considerable growth during the forecast period, owing to rise in prevalence of immune disorder and growth in healthcare expenditure.
By Application
Other Application segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.
By End User
On the basis of end user, the hospital segment dominated the blood plasma derivatives market in 2020, and this trend is expected to continue during the forecast period, owing to increase in prevalence of the chronic and infectious such as immunodeficiency disorder, hemophilia, and initiative taken by government and private organization to develop advance healthcare sector. However, the clinic segment is expected to witness considerable growth during the forecast period, owing to increase in number of clinic sector.
By End User
Hospital segment is projected as one of the most lucrative segment.
By Region
North America garnered a major share in the blood plasma derivatives market in 2020, and is expected to continue to dominate during the forecast period, owing to increase in number of approval of plasma derived product, and surge in number of key players to manufacture plasma derived product in the region. However, Asia-Pacific is expected to register highest CAGR of 11.0% from 2021 to 2030, owing to rise in prevalence of life-threatening diseases, and surge in awareness about the use of plasma derived product among physician and consumer.
By Region
North America was holding a dominant position in 2020 and would continue to maintain the lead over the analysis period.
Competition Analysis
Some of the major companies that operate in the global blood plasma derivatives market size include CSL Limited, Sanofi, Grifols, Kedrion Biopharma ,Inc., Octapharma AG, Takeda, Bayer AG, LFB S.A, Fusion Health Care Pvt. Ltd, Biotest AG
Key Benefits For Stakeholders
- The study provides an in-depth analysis of the blood plasma derivatives market, and the current trends & future estimations to elucidate imminent investment pockets.
- It presents a quantitative analysis of the market from 2021 to 2030 to enable stakeholders to capitalize on the prevailing blood plasma derivatives market opportunities.
- Extensive analysis of the market based on procedures and services assists to understand the trends in the industry.
- Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the blood plasma derivatives market.
Blood Plasma Derivatives Market Report Highlights
| Aspects | Details |
 By Type |
|
 By APPLICATION |
|
 By END USER |
|
 By Region |
|
 Key Market Players | Biotest AG, LFB S.A, Sanofi, Kedrion Biopharma ,Inc., Takeda, Fusion Health Care Pvt. Ltd, Octapharma AG, Grifols, CSL Limited, Bayer AG |
Analyst Review
This section provides opinions of the top-level CXOs operating in the global blood plasma derivative market. According to the insights of CXOs, the blood plasma derivative market is expected to exhibit high growth potential attributable to factors such as growth in blood plasma donors and awareness among consumer about plasma derived product and increase in number of key players for manufacturing blood plasma derivatives. In addition, rise in prevalence of immunodeficiency diseases and surge in number of approvals by the U.S. Food and Drug Administration (FDA) for advanced blood plasma derivatives drive the growth of the market.
CXOs further added that Asia-Pacific is expected to witness highest growth, in terms of revenue, owing to rise in prevalence of immunodeficiency diseases, increase in number of approvals for the blood plasma derivatives, and strong presence of key players.
The total market value of blood plasma derivative market is $36,471.9 million in 2020.
The forecast period in the report is from 2021 to 2030
The market value of blood plasma Market in 2021 was $39,827.3 million.
The base year for the report is 2020.
Yes, blood plasma derivative companies are profiled in the report.
The top companies that hold the market share in blood plasma derivative are market are Bayer AG, Biotest AG, CSL limited, Fusion Health Care Pvt. Ltd, Grifols ,S.A, Kedrion Biopharma ,Inc., LFB S.A, Octapharma AG, Sanofi, and Takeda
Asia pacific is expected to register highest CAGR 11.0% from 2021 to 2030, owing to increase in prevalence of Immunodefficiency disorder .
The key trends in the blood plasma derivative market are increase in prevalence of immunodefficiency disorders ; rise in awareness of immunodeficiency disorder .
Loading Table Of Content...
